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Cerebrospinal ﬂuid oxidative stress metabolites in
patients with bipolar disorder and healthy controls:
a longitudinal case-control study
Ulla Knorr 1, Anja Hviid Simonsen 2, Peter Roos2, Allan Weimann3,4, Trine Henriksen3,4, Ellen-Margrethe Christensen1,
Maj Vinberg1, Rie Lambæk Mikkelsen1, Thomas Kirkegaard1, Rasmus Nejst Jensen1, Morten Akhøj5, Julie Forman5,
Henrik Enghusen Poulsen4, Steen Gregers Hasselbalch2 and Lars Vedel Kessing1
Abstract
Bipolar disorder (BD) is a mental disorder characterized by recurrent relapses of affective episodes, cognitive
impairment, illness progression, and reduced life expectancy. Increased systemic oxidatively generated nucleoside
damage have been found in some neurodegenerative disorders and in BD. As the ﬁrst, this naturalistic prospective,
longitudinal follow-up case-control study investigated cerebrospinal ﬂuid (CSF) oxidative stress markers 8-oxo-7,
8-dihydroguanosine (8-oxoGuo) and 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG) that relate to RNA and DNA
damage, respectively. Patients with BD (n= 86, 51% female) and gender-and-age-matched healthy control individuals
(HC; n= 44, 44% female) were evaluated at baseline (T0), during (T1) and after a new affective episode (T2), if it
occurred, and after a year (T3). Cerebrospinal and urine oxidative stress markers were analyzed using ultra-performance
liquid chromatography–tandem mass spectrometry. CSF-8-oxoGuo was statistically signiﬁcantly higher by 18% (p=
0.003) in BD versus HC at T0, and by 22% (p= 0) at T3. CSF-8-oxoGuo had increased by 15% (p= 0.042) from T0 to T3,
and by 14% (p= 0.021) from T2 to T3 in patients, who experienced an episode during follow-up. CSF-8-oxodG had
increased by 26% (p= 0.054) from T0 to T2 and decreased by 19% (p= 0.041) from T2 to T3 in patients, who
experienced an episode during follow-up. CSF-8-oxoGuo did not show a statistically signiﬁcant change in HC during
the one-year follow-up. CSF and urine-8-oxoGuo levels correlated moderately. In conclusion, CSF oxidative stress
marker of RNA damage 8-oxoGuo showed both state and trait dependence in BD and stability in HC. Central RNA
damage may be a potential biomarker for BD.
Introduction
Bipolar disorder (BD) is a disabling mental illness with a
prevalence of 1%, a high risk of recurrence of manic and
depressive episodes, a lifelong elevated risk of suicide1 and
a heritability of 60–80%2. A vast body of literature evi-
dence show clinical progression in BD with increasing risk
of developing new mood episodes with every episode,
progressive shortening of inter-episode intervals with
each recurrence, and with increasing cognitive disabilities
during the course of illness1,3–8. However, systematic
research of the underlying neurobiology of illness pro-
gression is lacking.
Elevated levels of peripheral markers of oxidative stress
have been found in psychiatric disorders, diabetes, and
neurodegenerative disorders9–11. Oxidative stress reﬂects
an increase in pro-oxidants, which subsequently leads to
oxidative modiﬁcations of cellular components, such as
RNA and DNA12. Oxidative stress markers 8-oxo-7,8-
dihydroguanosine (8-oxoGuo), a marker of RNA oxida-
tion, and 8-oxo-7,8dihydro-2′-deoxyguanosine (8-oxodG),
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a marker of DNA oxidation, can reliably be quantiﬁed in
cerebrospinal ﬂuid (CSF)13 and urine14 using a modiﬁed
ultra-performance liquid chromatography and mass
spectrometry assay, and are valid markers of central/
whole-body RNA and DNA damage, respectively14.
We and other groups have found elevated levels of
urine-8-oxoGuo and 8-oxodG in patients with BD com-
pared to healthy control individuals (HC)9,15–17. Fur-
thermore, in a longitudinal study our group has found
increased oxidative stress in manic/hypomanic states
versus remission17. Postmortem measurements indicate
DNA as the main site of oxidative stress modiﬁcations in
the central nervous system in severe mental illnesses and
suggested that 8-oxoGuo may pass the blood–brain bar-
rier more readily than 8-oxodG18. Data are largely missing
on oxidative stress evolution during progression of BD11
and as recently reviewed, CSF oxidative stress has not yet
been investigated in either BD or HC 19.
This study aimed, as the ﬁrst, to investigate state-spe-
ciﬁc, intra-individual changes in repeated measures of
cerebrospinal and urinary markers of oxidative stress in
outpatients diagnosed with BD compared to HC indivi-
duals during a one-year prospective, longitudinal follow-
up study.
The following hypotheses were tested: Cerebrospinal
and urinary oxidative stress marker levels are: (1) higher
in patients with BD compared to HC, (2) stable during a
year in HC, (3) increased during and following an affective
episode, and (4) correlated.
Participants and methods
Setting
The study was conducted at the Copenhagen Affective
Disorder Research Center. Participants for the study were
investigated from 1 April 2014 until 27 April 2017. All
participants were assessed at baseline (T0) and after a
follow-up of one year (T3). The mood states of patients
with BD were evaluated by weekly contacts. In case of a
new affective episode of depression, hypomania or mania
patients were reassessed during the episode (T1) and at
the time they had regained remission (T2; Table 1).
All participants provided written informed consent and
were reimbursed regarding lumbar puncture.
Participants
Patients with BD
Newly diagnosed patients aged 18–60 years with BD in
remission were recruited from the Copenhagen Affective
Disorder Clinic that receives patients from the Capital
Region of Denmark covering 1.6 million people and all
psychiatric centres in the region20. Diagnoses were initi-
ally provided by experienced psychiatrists in the Clinic.
Exclusion criteria were signiﬁcant physical illness, preg-
nancy or planned pregnancy within a year, substance
abuse, expected noncompliance with the protocol, no
informed consent, and ﬁnally practical reasons.
Healthy control individuals
Age-and-gender-matched HC with no personal or ﬁrst-
degree family history of psychiatric disorders were
recruited among blood donors aged 18–60 years afﬁliated
to the Blood Bank at Frederiksberg Hospital, Copenhagen
as in prior studies from our group21. Exclusion criteria
were the same as for the patients.
Clinical assessment
Baseline T0
Written and oral information of the study was given to
patients with BD at the Copenhagen Affective Disorder
Clinic and at the Blood Bank for the HC followed up by a
personal contact by e-mail or telephone. After giving
informed consent, the participants were examined at
baseline (T0). The clinical diagnosis was evaluated using
the semistructured Schedules for Clinical Assessment in
Neuropsychiatry (SCAN) interview22 conducted by spe-
cialist in psychiatry (U.K.). The severity of mood symp-
toms was assessed using the 17-item Hamilton
Depression Rating Scale (HAMD)23 and the Young Mania
Rating Scale (YMRS)24. Remission was deﬁned as scores
below 8 on both scales for at least two weeks. Further-
more, clinical characteristics were assessed, including
weight, height, current medication, alcohol consumption,
smoking habits, duration of illness from ﬁrst hypomanic
episode, and history of psychoses. Severity of illness was
estimated using the Global Clinical Impression Scale25.
Follow-up T1, T2, and T3
All participants were followed prospectively for a year.
The patients received treatment as usual and were
instructed to daily self-monitoring of mood, sleep, alco-
hol, and medicine intake. Psychiatrist U.K. kept in weekly
contact with the patients by their choices of either tele-
phone, short message service, or e-mail. Patients who
experienced a moderate to severe affective episode
deﬁned as scores above 13 points on either the HAMD or
the YMRS for at least two weeks, had a repeated clinical
assessment, including urine, blood, and CSF sampling
during the episode (T1) and, also following the episode
when being in stable remission for at least two weeks (T2).
Finally, all participants were assessed at the one-year
follow-up in remission, deﬁned as at least eight weeks in a
stable remission state (T3), see Flowchart, Fig. 1. On the
basis of prior data from the Copenhagen Affective Dis-
order Clinic26, we expected that 50% of the patients would
experience an affective episode during the follow-up
period.
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Biological assessments
The participants (fasted overnight before the collection
of CSF, blood, and urine samples between 0800 and
1000 h in the morning. At all timepoints (T0, T1, T2, and
T3), the clinical assessments and the urine, blood, and
CSF sampling from the participants were done on the
same or the following day.
Sampling and handling of CSF
Specialists of neurology (S.G.H. and P.R.) performed
lumbar puncture to collect CSF samples from patients
with BD and HC individuals in the lateral decubitus
position. The spinal needle was inserted into the L3/L4 or
L4/L5 interspace, and a total volume of 10–12ml of CSF
was collected in polypropylene tubes, and gently inverted
to avoid gradient effects. Samples where centrifuged on
acquisition at 2,000 g for 10 min at +4 °C and stored in
polypropylene tubes in 250 µL aliquots at −80 °C pending
analysis. A general CSF screen was conducted, including
albumin, immunoglobulin G (IgG), IgG index, ery-
throcytes, white blood cells, glucose, and protein.
Blood sampling
Board-certiﬁed laboratory technicians collected blood
samples that were analyzed at the Clinical Biochemical
Laboratory at Rigshospitalet, Denmark, regarding standard
Table 1 Clinical characteristics of patients with bipolar disorder and healthy control individuals.
BD
baseline (T0)
HC
baseline (T0)
p value BD after an
episode (T2)
BD follow-up
(T3)
HC follow-up
(T3)
p value
N (% female) 86 (51) 44 (54) 0.581a 32 (50) 73 (52) 41 (53) 0.846a
Age, median (Q1; Q3) 33 (25; 42) 31 (24; 41) 0.526b 35 (25; 41) 35 (26; 42) 30 (24; 40) 0.352b
Bipolar type I, N (%) 49 (57) 18 (56) 43 (58)
Bipolar type II, N (%) 37 (43) 14 (44) 31 (42)
Clinical Global Impression, mean (s.d.) 4.6 (0.6) 4.6 (0.6) 4.8 (0.6)
Duration of illness, N years, mean (s.d.) 12.4 (9.8)
Prior psychosis, N (%) 36 (41) 13 (41) 31 (42)
First and second-degree family members
with affective disorder, N (mean)
2.25 (1.9) 0
Young mania rating scale, median (Q1; Q3) 1 (0; 2) 0 (0; 0) <0.001 0 (0; 1) 0 (0; 1) 0 (0; 0) <0.001
Hamilton depression rating scale 17 items 3 (1; 5) 0 (0; 0) <0.001 3 (1; 6) 2 (0; 4) 0 (0; 0) <0.001
Daily alcohol consumption, median (Q1; Q3) 0.2 (0; 1) 0.5 (0; 1) 0.375b 0.1 (0; 0.5) 0.3 (0.1; 1) 1 (0.3; 1.2) 0.015c
Smokers, N (%) 28 (34) 8 (18) 0.096a 14 (42) 25 (34) 8 (20) 0.132a
Daily cigarettes, median (min; max) 14.5 (0.2; 20) 3.5 (0.5; 30) 0.026b 16 (5; 20) 12 (0.5; 35) 2.5 (0.1; 20) 0.032b
BMI, mean (s.d.) 25.3 (4.9) 24.9 (3.4) 0.659 24.9. (3.9) 25.6 (5.2) 25.6 (3.7) 0.973
Lithium, N (%) 44 (51) 18 (56) 40 (54)
Antipsychotics, N (%) 33 (38) 18 (56) 25 (34)
Anticonvulsants, N (%) 43 (50) 22 (69) 37 (50)
Antidepressants, N (%) 2 (2) 1 (3) 4 (5)
Benzodiazepines, N (%) 6 (7) 7 (22) 9 (12)
CSF 8-oxoGuo (pmol/L), median (Q1; Q3) 54.8 (47.3; 68) 48.1 (39.3; 56.4) <0.001 61.5 (54.6; 2.4) 51.8 (41.2; 58.8) <0.001
Urine 8-oxoGuo (nmol/mmol creatinine),
median (Q1; Q3)
1.8 (1.5; 2.1) 1.5 (1.3; 1.8) <0.001 1.6 (1.4; 2) 1.2 (1.1; 1.5) <0.001
CSF 8-oxodG (pmol/L) median (Q1; Q3) 6.5 (4.6; 8.9) 5.4 (3.1; 7) 0.016 6.9 (5.8; 8.2) 5.9 (4.5; 7.3) 0.196
Urine 8-oxodG (nmol/mmol creatinine),
median (Q1; Q3)
1.4 (1.1; 1.7) 1.3 (1; 1.4) 0.069 1.3 (1.1; 1.6) 1.1 (0.9; 1.3) <0.001
Summary statistics are N (%) for categorical data, mean (s.d.) for normally distributed continuous data and median (lower quartile; upper quartile) for non-normally
distributed continuous data
BD patients with bipolar disorder, HC healthy control individuals
aFisher’s exact test; bdata log-transformed, p values are t-tests of medians are the same; c“Wilcoxon rank” test
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biochemical parameters, including hematological para-
meters, blood glucose, C-reactive protein, thyroid hor-
mones, lipid status, ions, metabolites, liver enzymes, and
lithium levels.
Urine sampling
A freshly voided spot urine was obtained using a stan-
dard sampling kit without any additives. The sample was
kept on ice and centrifuged at 4 °C and 1590 g for 15 min,
after which aliquots of 1.5 ml were transferred to
Eppendorf tubes and stored at −80 °C pending analyses.
The results for oxidative stress markers in urine were
normalized for creatine27.
Analyses of 8-oxoGuo and 8-oxodG
The cerebrospinal and urinary oxidative stress markers 8-
oxoGuo and 8-oxodG were analyzed at Laboratory of Clin-
ical Pharmacology, Rigshospitalet using ultra-performance
T0
T1
T2
T3
Euthymic paents with bipolar disorder at 
baseline(n=86) 
Missing data: (n=1)
Urine (n=85) and CSF (n=62)
Healthy control individuals at base line (n=44)
Urine (n=44) and CSF (n=40)
Lost to follow-up (n=6):
Declined follow-up 
(n=3) 
Pregnancy (n=1) 
Le country during 
phase (n=2) 
Paents with an aﬀecve 
phase during follow up (n=36)
Missing data: (n=1)
Urine (n=35) and CSF (n=22)
Lost to follow-up (n=2)  
Could not be reached 
(n=1) 
Moved: (n=1) 
Paents euthymic aer an 
aﬀecve phase (n=34)
Missing data: (n=1)
(urine missing): (n=1)
Urine (n=32) and CSF (n=20)
Lost to follow-up (n=5):
Declined follow-up 
(n=2) 
Moved (n=1) 
Could not be reached 
(n=1)
Paents euthymic at one-year 
follow-up (n=29)
Urine (n=29) and CSF (n=15)
Lost to follow-up (n=3):
Could not be reached 
(n=2) 
Depression (n=1) 
Paents euthymic at one year 
follow-up with no phases 
(n=44)
Urine (n=44) and CSF (n=25)
Healthy control individuals at 
one-year follow-up (n=41)
Urine (n=41) and CSF (n=28)
♦
♦
♦
♦
♦
♦
♦
♦
♦
♦
Fig. 1 Flowchart for the Bipolar Oxidative Stress Follow-up Study.
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liquid chromatography–tandem mass spectrometry, as
described in full detail elsewhere 13,27.
Statistical analyses
Data were analyzed according to a preestablished pro-
tocol. All analyses were conducted with SAS software,
version 9.4, (Copyright 2013, SAS Institute Inc., Cary, NC,
USA). All p values were corrected for multiple testing
using the Benjamini & Hochberg procedure28. We applied
a conservative cutoff for the false discovery rate at 0.05,
which limits the rate of false positives among the reported
ﬁndings to one in 20, so that an adjusted p ≤ 0.05 was
considered statistically signiﬁcant. All biomarkers were
found to have a skew distribution and were therefore log-
transformed prior to analysis. Hence, estimated differ-
ences between groups and timepoints are expressed in
relative terms as percent-wise differences.
Regarding sample size and power, the numbers of par-
ticipants in this present study, including 86 patients with
BD and 44 HC individuals are like the largest prior case-
control studies, regarding peripheral oxidative stress
markers in BD15–17.
Demographic and clinical data
Demographic and clinical data at timepoints T0, T2,
and T3 were summarized in numbers and percentages
(categorical data), means and s.d. (normally distributed
continuous data), and medians and quartiles (non-nor-
mally distributed continuous data). Comparisons of BD
and HC at T0 and T3 was made using Fisher’s exact test,
Welch’ t-test or the Mann–Whitney U test, whichever
was most appropriate.
Markers of oxidative stress in BD and HC at baseline and at
the one-year follow-up
To compare biomarker levels of CSF-8-oxoGuo, CSF-8-
oxodG, urine-8-oxoGuo, and urine-8-oxodG between BD
and HC, a linear mixed model was applied with time (T0
or T3) and group (BD or HC) as ﬁxed effects and with an
unstructured covariance to account for correlation
between the repeated measurements on the study parti-
cipants. The analyses were performed in three versions,
version 1: no adjustment for potential confounders; ver-
sion 2: adjusted for gender, age, and body mass index
(BMI); version 3: adjusted for gender, age, BMI, alcohol
consumption, and smoking. Estimated differences
between BD and HC are reported for biomarker levels at
T0, biomarker levels at T3, and change in biomarker level
from T0 to T3.
The analyses were repeated with further stratiﬁcation of
BD into the participants who either had or had not
experienced an episode during follow-up.
Internal validity of the measured biomarkers was eval-
uated by comparing their levels at baseline and follow-
up in HC.
Patients with BD, who had an affective episode during
follow-up
A subgroup analysis was performed to evaluate changes
in biomarker levels in patients with BD, who had
experienced an affective episode during follow-up. To this
end, a linear mixed model with timepoint (T0, T1, T2, T3)
as ﬁxed effect and an unstructured covariance was
applied. Estimates were reported for changes between the
timepoints. The analysis was performed in two versions,
version 1: no adjustment for potential confounders; and
version 2: adjusted for gender, age, BMI, and the three
mood stabilizers lithium, quetiapine, and lamotrigine.
Correlations between CSF and urinary measures of oxidative
stress
Spearman and Pearson correlations were estimated
between CSF and urine 8-oxoGuo and 8-oxodG at time-
point T0 and T3, and in BP and HC separately.
Effect of dose of lithium, quetiapine, lamotrigine and
smoking on CSF and urinary measures of oxidative stress
To investigate the effect of the three mood stabilizers,
we applied a linear mixed model as previously described29,
which distinguishes the cross-sectional effect (i.e., the
effect of the average dose of the drug over time) from the
longitudinal effect (i.e., the effect of changes in the dose of
the drug over time) in order to address potential biases
due to unmeasured confounders. In mixed models, the
effect of smoking on each of the four outcomes was
estimated with inclusion of data from all four timepoints.
Sensitivity analyses
All analyses were repeated including and excluding
outliers. This did not alter the results to any signiﬁcant
extent. We report data including outliers.
Results
Inclusion, demographics, clinical, and study characteristics
Out of a total of 497 eligible patients with BD, 86
patients were included in the study in remission. A total of
411 did not enter the study due to: not obtaining remis-
sion before the inclusion ended in January 2016 (n= 57),
signiﬁcant physical illness (n= 97), pregnancy or planned
pregnancy (n= 62), substance abuse (n= 26), expected
noncompliance with the protocol (n= 90), not giving
informed consent (n= 49), and discharge from the clinic
before an informed consent could be obtained (n= 30).
Demographics and clinical characteristics of the parti-
cipants of the study are presented in Table 1. A total of 24
participants (BD= 15, HC= 9) received medical
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treatment for a stabilized physical disorder or as hormone
anticonception: hypertension (BD= 1), diabetes mellitus
type II (BD= 1), hypothyroidism (BD= 3, HC= 1), and
hormonal contraceptives (BD= 10, HC= 9). Patients were
most frequently treated with lithium, lamotrigine, and
quetiapine, but three patients did not get any psychotropic
medication at inclusion.
A total of 44 HC were included in the study. Patients
with BD and HC individuals were well matched according
to age, gender and, BMI at baseline and there were no
differences either at follow-up. There were more smokers
among patients with BD at baseline and at follow-up
alcohol intake was higher in HC individuals.
The ﬂow chart (Fig. 1) shows that 36 patients with BD
developed a new affective episode during follow-up and of
these 34 reached stable remission within the study period.
The completion rates from baseline to follow-up for
patients with BD and HC were 65% versus 86% regarding
CSF, and 70% versus 93% regarding urine samples. All
together 62 patients with BD and 40 HC gave samples of
both CSF and urine at baseline. All participants, but one,
provided a urine sample at baseline (BD= 85, HC= 44).
Levels of cerebrospinal and urinary oxidative stress marker
levels in patients with BD compared to HC
CSF-8-oxoGuo was statistically signiﬁcantly higher by
18% (95% conﬁdence interval (CI) 8–28%, adj-p= 0.003)
in patients with BD versus HC at baseline, and by 22%
(95% CI 12–34%, adj-p= 0) at follow-up.
Urine-8-oxoGuo was statistically signiﬁcantly higher by
17% (95% CI 8–27%, adj-p= 0.003) in patients with BD
versus HC at baseline, and by 30% (95% CI 16–45%,
adj-p= 0) at follow-up.
CSF-8-oxodG was statistically signiﬁcantly higher by
29% (95% CI 6–55%, adj-p= 0.043) at baseline, and urine-
8-oxodG was statistically signiﬁcantly higher by 25% (95%
CI 10–43%, adj-p= 0.005) at follow-up in BD versus HC.
CSF-8-oxodG was higher by 13% at follow-up and urine-
8-oxodG was higher by 12% at baseline in patients with
BD versus HC, but these differences were not statistically
signiﬁcant in the adjusted models (Fig. 2 and Table 2).
When patients with BD were divided into subgroups
with and without a new affective episode during follow-
up, no statistically signiﬁcant differences in the oxidative
stress marker levels were found between the subgroups at
the timepoints baseline (T0) and follow-up (T3) (Sup-
plemental Table 1). Furthermore, when considering the
relative changes from T0 to T3 in the subgroups with and
without an episode during follow-up compared to HC, no
differences were found in the relative changes between T0
and T3 (Supplemental Table 2).
Regarding the internal validity of the biomarkers only
CSF-8-oxoGuo did not show a statistically signiﬁcant
change in HC during the one-year follow-up (Supplemental
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Fig. 2 Cerebrospinal ﬂuid and urine levels of 8-oxoGuo and 8-oxodG in patients with bipolar disorder with and without an episode during follow-up
and healthy control individuals at baseline (T0), during (T1), and after (T2) an episode, did it occur and, at one-year follow-up.
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Table 3). On the contrary, CSF-8-oxodG in HC increased
signiﬁcantly by 22% while urine-8-oxoGuo and urine-8-
oxodG decreased signiﬁcantly by 15 and 14%, respectively
(Supplemental Table 3).
Changes in levels of cerebrospinal and urinary oxidative
stress marker levels in patients with BD during and
following an affective episode
CSF-8-oxoGuo had increased by 15% (95% CI 4–27%,
adj-p= 0.042) from T0 to T3, and by 14% (95% CI 6–23%,
adj-p= 0.021) from T1 (during an episode) to T3 in
patients who experienced an episode during follow-up
(Table 3).
CSF-8-oxodG had increased by 26% (95% CI 5–51%,
adj-p= 0.054) from T0 to T2 (after an episode) and
decreased by 19% (95% CI −30–6%, adj-p= 0.041) from
T2 to T3 in patients who experienced an episode during
follow-up.
No statistically signiﬁcant changes were found in the
other CSF and urinary oxidative stress markers or
between any of the remaining timepoints (Table 3).
Correlations between cerebrospinal and urinary oxidative
stress markers
Measures of cerebrospinal and urinary oxidative stress
markers of nucleoside damage correlated in separate
analyses of all participants, patients with BD and HC
(Supplemental Table 4).
Strong statistically signiﬁcant correlations were found
between CSF-8-oxoGuo and CSF-8-oxodG in patients,
with BD and HC individuals at both baseline and follow-
up. Weak to moderate statistically signiﬁcant correlations
were found between CSF-8-oxoGuo and urine-8-oxoGuo
in patients, with BD and HC individuals at both baseline
and follow-up. Furthermore, moderate statistically sig-
niﬁcant correlations were found between CSF-8-oxodG
and urine-8-oxodG in patients, with BD and HC indivi-
duals at baseline and follow-up regarding HC individuals.
However, a weak correlation between CSF-8-oxodG and
urine-8-oxodG was not statistically signiﬁcant in patients
with BD at follow-up (Supplemental Table 4).
The inﬂuence of medication on oxidative stress markers
Measures of cerebrospinal and urinary oxidative stress
markers of nucleoside damage tended to increase with
increasing doses of lithium. The longitudinal effect, i.e.,
the effect of individual changes in dose of lithium was the
strongest on CSF-8-oxoGuo (+0.9% per mmol increase in
dose, 95% CI 0.3–1.6%, p-adj= 0.04) and remained sta-
tistically signiﬁcant in multivariate analysis and after
adjustment for multiple testing. A similar effect was only
borderline statistically signiﬁcant on CSF-8-oxodG
(+1.2% per mmol increase in dose, 95% CI 0.3–2.2%,
p-adj= 0.06). No signiﬁcant effects of increasing doses ofTa
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quetiapine and lamotrigine were found in 8oxoGuo and
8oxodG in either CSF or urine (Supplemental Table 5).
The inﬂuence of other covariates on oxidative stress
markers in patients with BD
As predicted, measures of cerebrospinal and urinary
oxidative stress markers of nucleoside damage depend on
age and gender. However, there was no general effect of
other covariates, including smoking and alcohol (Sup-
plemental Table 6).
Discussion
This study conﬁrmed that levels of CSF-8-oxoGuo: (1)
were statistically signiﬁcantly higher at both baseline and
follow-up in patients with BD compared to HC, (2)
showed internal validity since the values in HC did not
change from baseline to follow-up, (3) increased following
an affective episode in patients with BD, and (4) correlated
moderately with levels of urine-8-oxoGuo. Thus, cere-
brospinal oxidative stress markers of RNA damage 8-
oxoGuo showed both state and trait dependence in BD
and stability in HC. In subgroup comparisons between
patients with BD either with or without an episode during
follow-up, a new affective episode was not predictable
from baseline levels of oxidative stress markers.
Explorative analyses showed that increasing doses of
lithium were associated with an increase of cerebrospinal
and urinary oxidative stress markers, but this may likely
Table 3 Changes in cerebrospinal ﬂuid and urinary oxidative stress markers levels of 8-oxoGuo and 8-oxodG in patients
with bipolar disorder who had an affective episode during a one-year follow-up.
Outcome b Version 1, b1 p value (adj.) Lower Upper Version 2, b2 p value (adj.) Lower Upper
CSF 8-oxoGuo T3/T0 1.16 0.004 (0.023) 1.05 1.27 1.15 0.01 (0.042) 1.04 1.27
T2/T0 1.12 0.027 (0.094) 1.01 1.23 1.09 0.131 (0.0275) 0.97 1.22
T1/T0 1.02 0.512 (0.661) 0.96 1.09 1.01 0.815 (0.898) 0.93 1.09
T3/T1 1.13 0.004 (0.021) 1.05 1.22 1.14 0.004 (0.021) 1.06 1.23
T2/T1 1.09 0.059 (0.158) 1.00 1.20 1.08 0.116 (0.252) 0.98 1.19
T3/T2 1.03 0.477 (0.634) 0.94 1.14 1.06 0.27 (0.435) 0.95 1.17
Urine 8-oxoGuo T3/T0 0.97 0.588 (0.735) 0.86 1.09 0.92 0.162 (0.316) 0.82 1.03
T2/T0 0.97 0.506 (0.655) 0.87 1.07 0.95 0.43 (0.586) 0.85 1.07
T1/T0 0.97 0.409 (0.569) 0.90 1.05 0.94 0.199 (0.352) 0.86 1.03
T3/T1 1.00 0.991 (0.997) 0.90 1.11 0.98 0.669 (0.807) 0.87 1.09
T2/T1 1.00 0.943 (0.98) 0.90 1.10 1.01 0.829 (0.909) 0.91 1.12
T3/T2 1.00 0.949 (0.98) 0.92 1.10 0.97 0.362 (0.522) 0.89 1.04
CSF 8-oxodG T3/T0 1.05 0.5 (0.655) 0.90 1.23 1.02 0.757 (0.871) 0.88 1.19
T2/T0 1.25 0.001 (0.008) 1.10 1.41 1.26 0.014 (0.054) 1.05 1.51
T1/T0 1.05 0.565 (0.712) 0.89 1.22 1.09 0.322 (0.486) 0.92 1.28
T3/T1 1.01 0.915 (0.977) 0.86 1.18 0.94 0.114 (0.249) 0.87 1.02
T2/T1 1.19 0.045 (0.133) 1.00 1.42 1.16 0.127 (0.273) 0.95 1.41
T3/T2 0.85 0.038 (0.116) 0.72 0.99 0.81 0.01 (0.042) 0.70 0.94
Urine 8-oxodG T3/T0 0.96 0.4 (0.56) 0.87 1.06 0.94 0.182 (0.332) 0.85 1.03
T2/T0 0.93 0.134 (0.278) 0.84 1.02 0.89 0.03 (0.1) 0.81 0.99
T1/T0 0.99 0.88 (0.954) 0.90 1.09 0.97 0.482 (0.638) 0.98 1.07
T3/T1 0.97 0.474 (0.634) 0.87 1.07 0.97 0.562 (0.711) 0.87 1.08
T2/T1 0.93 0.19 (0.341) 0.84 1.04 0.92 0.165 (0.317) 0.82 1.04
T3/T2 1.03 0.4 (0.56) 0.96 1.12 1.05 0.222 (0.379) 0.97 1.14
Estimates b were reported for changes between the timepoints: T1–T0, T2–T0, T3–T0, T2–T1, T3–T1, and T3–T2. The analysis was performed in two versions. Version 1:
no adjustment for potential confounders; and version 2: adjusted for gender, age, BMI, and the three mood stabilizers lithium, quetiapine, and lamotrigine. p values
corrected for multiple testing are in brackets.
T0 baseline, T1 during an episode, T2 after an episode, T3 at one-year follow-up, adj. adjusted
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be a result of confounding by indication (higher doses of
lithium prescribed for more severe BDs). Furthermore,
prior studies suggested that lithium was associated with
decreased peripheral oxidative stress marker levels in
euthymic patients with BD30–32.
This study found different pathophysiological char-
acteristics in centrally and systemically generated oxida-
tive stress. The results suggest that a possible pathogenic
effect may be found down-stream from DNA, since no
statistically signiﬁcant differences between BD and HC
were found regarding DNA damage measured by
8-oxodG, but merely in 8-oxoGuo that represents RNA
damage. Also, the only weak to moderate correlation
between centrally and systemically generated oxidative
stress emphasize a role of the blood–brain barrier.
The ﬁndings regarding urinary oxidative stress from the
present study are consistent with prior ﬁndings from our
group, showing increased levels of urine markers of oxi-
dative stress in unipolar depression33, BD rapid cycling16,
BD type I17, and schizophrenia34. In these prior studies,
state dependencies were found only in patients diagnosed
with BD type I between the states of mania and stable
remission17.
Increased levels of oxidative stress may predict mortality
in patients with other chronic diseases such as diabetes35.
Epidemiological studies have found that the life expec-
tancy among patients with BD is decreased by 8–12 years
compared to the general population36 and that patients
die due to natural causes of death already from adoles-
cence37. It is a possibility that increased levels of oxidative
stress seen in patients with BD may contribute to the
decreased life expectancy by inducing accelerated ageing.
The present results suggest that relapses of affective epi-
sodes may increase oxidative stress. This gives hope that
effective long-term preventive treatment may contribute
to normalized life expectancy in BD. Furthermore, our
ﬁndings suggest that CSF oxidative stress may represent
state (increased at T1) and trait markers (increased at T2
and T3) in BD, and may reﬂect neurobiological correlates
of illness progression and sensitization5,38 in BD.
Mitochondrial dysfunction reﬂected as increased oxi-
dative stress may be a biological underpinning of BD11,39,
and impaired autophagy has been suggested as the link
between mitochondrial dysfunction and psychiatric
disorders11.
Overall, our ﬁndings show that central RNA damage
may be related to the pathogenesis of BD.
Limitations
Only a total of 36 patients (42%) experienced an affec-
tive episode during the follow-up period and the subjects
had fewer repeated CSF samples than urine samples. Data
were analyzed using linear mixed models, which implicitly
imputes missing data from missed samples and drop outs,
and provides unbiased results under the assumption that
missing data is missing at random. However, results may
still be biased if missingness depends on confounding
factors that are not accounted for. Smoking was more
prevalent in BD compared to HC. However, analyses of
the effect of smoking showed no signiﬁcant effect in uni-
and mulitivariate analyses. Estimates and p values
remained signiﬁcant after adjusting for alcohol and
smoking. Clinical researchers (U.K., S.G.H., and P.R.) were
not blinded to the participant being BD or HC. However,
they did not participate in the statistical analyses of the
oxidative stress markers that for all practical reasons were
blinded.
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